The October issue of @ThyroidJournal is now available online! https://t.co/0RVGO14ykF @amthyroidassn #ThyroidJournal #endotwitter #medtwitter

Which factors predict survival in thyroid cancer patients with brain metastases? A new @ThyroidJournal meta-analysis by a team from @MDAndersonNews found worse outcomes with ATC, poor performance status, multiple brain mets & distant disease. https://t.co/TZodH2TUJe

Does immunotherapy improve survival in anaplastic thyroid cancer? Check out this new @ThyroidJournal analysis of >3,000 patients which found IT use may be linked to longer overall survival, especially with surgery & radiation. https://t.co/hVlrWTLBTT

In a new article in @ThyroidJournal, a team from China found targeting B7-H3 in cancer-associated fibroblasts with nanosystems suppressed Anaplastic Thyroid Cancer progression in mice, reducing tumor growth & invasion, highlighting a promising therapy. https://t.co/gcrpoJPHLY

Does the type of treatment for hyperthyroidism alter your mortality risk? This new systematic review & network meta-analysis from @BU_Tweets in @ThyroidJournal finds surgery may be linked to lower all-cause & cardiovascular mortality vs ATDs or RAI. https://t.co/a9VkYMpwEU

Are AI models for thyroid cancer equitable? Check out this new systematic review by a team from Toronto in @ThyroidJournal of 197 studies which finds some gaps in demographic representation, raising concerns about bias in diagnosis and care. https://t.co/9F66KwPTcD

Can teprotumumab rescue vision in steroid- and surgery-resistant dysthyroid optic neuropathy in TED? In this small case series, 88% of eyes showed recovery, with rapid, sustained improvement in visual acuity and field. Promising, but more data needed. https://t.co/sSqpaCjyRn

Are isolated TERT promoter mutations just as risky as combo mutations in #thyroidcancer? This new study @ThyroidJournal shows iTERT still carries high malignancy risk (67%)—and 1/3 are aggressive subtypes, indicating a strong case for total thyroidectomy. https://t.co/9PL7DKKsSr

The September issue of @ThyroidJournal is now available online! https://t.co/nVHxr6OM7n @amthyroidassn #ThyroidJournal #endotwitter #medtwitter

Which RET thyroid cancer drug do patients tolerate best? Check out the results of this new phase 3 multinational trial (LIBRETTO-531) in @ThyroidJournal compares selpercatinib vs cabozantinib/vandetanib regarding side effects & better quality of life. https://t.co/Mi5JniaLbG

Could the statins prevent thyroid eye disease (TED) in Graves’ disease? Does it matter when they are started? Check out this new article from Taiwan showing that starting statins within 1 yr may cut severe orbitopathy risk by >60% in a nationwide cohort. https://t.co/FRClJxKVZm

Can multikinase inhibitors make “inoperable” thyroid cancers operable? This new review by @ClevelandClinic discusses the use of neoadjuvant MKIs (esp. lenvatinib) found to shrink locally advanced DTC, enabling surgery in >80% of cases reviewed. https://t.co/eDR53GfX8w

Can unstimulated Tg + doubling rate guide recurrence risk in #thyroidcancer? Check out this new study from Japan in @ThyroidJournal which shows how uTg and Tg-DR under TSH suppression may be a useful prognostic variable in PTC patients post-thyroidectomy. https://t.co/cn8KS9Zws5

Honored to speak in the Core Thyroidology Track at @AmThyroidAssn Meeting—case-based discussions + key pearls on imaging risk stratification, workup, molecular testing, and interactive Q&A. Always rewarding to connect science with #patient care #ThyroidCancer #atathyroid2025

So proud of our IM resident, Dr Julia Patton for her first ATA presentation. Early surgery with multidisciplinary involvement is key to recalcitrant Amiodarone induced hyperthyroidism. #atathyroid2025 @HenryFordHealth

Another wonderful #atathyroid2025 meeting with a strong @MDAndersonNews representation! Especially proud of @A_AbubakerMD and @JorgeArpiP for their strong work presenting the team’s translational and clinical data! Already looking forward to next year’s meeting!

What if thyroid hormone analogs could treat not just thyroid disease, but MASH & rare genetic disorders? 🧬 A new article @ThyroidJournal discusses recent FDA approval of resmetirom & EMA approval of Triac—signaling a new era of organ-targeted therapies. https://t.co/J39tiFBbnX

Primary thyroid lymphoma is rare—but outcomes are improving. What’s driving the change? @NIH researchers analyze 45+ years of data in @ThyroidJournal, uncovering key trends and survival factors. https://t.co/ErcI0MzOgH

Over 20% of pediatric thyroid cancer patients still have persistent disease 15+ years after diagnosis. Why does this happen—and who’s most at risk? This Italian team explores the answers in @ThyroidJournal. https://t.co/PVY6sz1IvT

The August issue of @ThyroidJournal is now available online! https://t.co/XcNnsh7RQn @amthyroidassn #ThyroidJournal #endotwitter #medtwitter